Key facts
- Forge Genetics’s last known valuation is $13.7M (Aug 2025).
- It has raised $3.0M; the latest was Early Stage VC ($2.7M) in Aug 2025.
- Notable investors include British Business Bank, Mercia Ventures, Midlands Engine Investment Fund, University of Nottingham.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Forge Genetics
- ·The full record, as it builds
Funding rounds
No funding rounds for Forge Genetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Forge Genetics
Developer of a genetic engineering tool designed to support targeted modifications in difficult-to-engineer microbial strains. The company offers an RNA-guided method that operates without CRISPR, enabling biotech researchers and industrial microbiologists to control editing and retention of intellectual property.
- Sector
- Healthcare
- HQ
- Nottingham, United Kingdom
- Founded
- 2023
- Employees
- 10
- Website
- forgegenetics.com/
- Ownership
- Privately Held (backing)
Forge Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Forge Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Forge Genetics in its N-PORT filings yet. We sweep new filings monthly.